Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Erratic market delays Transoma IPO

This article was originally published in Clinica

Executive Summary

Implantable wireless diagnostics specialist Transoma Medical has said it is postponing its IPO due to the current unpredictable economic climate in the US. The Minnesota-based firm told the Minneapolis/St Paul Business Journal that it still plans to go ahead with the IPO on the Nasdaq Stock Exchange. The offering was originally filed in October 2007 and is expected to raise $75m (see Clinica No 1278, p 8). Transoma was planning to use the funding to develop chronic cardiovascular disease technology and its Sleuth implantable ECG monitoring system. The company will be looking to avoid the fluctuating market conditions that have affected Enteromedics, another St Paul-based company that recently floated on the Nasdaq. Enteromedics, a neuroblocking technology company also based in St Paul, saw its share price fall by 11% from $8.73 per share to $7.76 during the last week.

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts